Filing identity and business context
Important metadata discrepancy: The supplied filing is NeoStem, Inc.’s Form 10-Q for the quarter ended September 30, 2013, not a 2012 Q3 filing for Lisata Therapeutics, Inc. The financial information below summarizes the filing provided.
NeoStem operated in one reportable segment, Cell Therapy, combining its PCT contract development and manufacturing services with development of cell therapy candidates, including AMR-001 and Treg programs. The comparative periods are the three and nine months ended September 30, 2013 and 2012. Share and per-share figures reflect the July 2013 1-for-10 reverse stock split.
Key financial metrics
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Revenue | $3.71 million | $4.43 million | $10.59 million | $11.58 million |
| Gross profit (margin) | $0.73 million (20%) | $0.69 million (15%) | $0.99 million (9%) | $2.14 million (18%) |
| Operating loss | $9.31 million | $8.09 million | $26.31 million | $22.44 million |
| Net loss from continuing operations | $9.28 million | $8.55 million | $26.77 million | $23.77 million |
| Net loss, including discontinued operations | $9.28 million | $8.40 million | $26.77 million | $51.03 million |
| Cash used in operating activities, continuing operations | Not presented by quarter | $19.74 million | $16.40 million |
At September 30, 2013, cash and cash equivalents were $16.95 million, working capital was approximately $10.3 million, total assets were $57.79 million, and total equity was $35.13 million. Notes payable totaled approximately $0.75 million and mortgages payable $3.29 million. Current liabilities were $10.04 million. The filing classifies both mortgages as current; covenant noncompliance and waivers are discussed below.
Material changes and drivers
- Quarterly revenue declined 16%; nine-month revenue declined 9%. Quarterly clinical services revenue fell, largely because fewer process-development contracts were completed and recognized. Manufacturing revenue and processing and storage services increased.
- Nine-month gross margin contracted to 9% from 18%, as costs of revenue rose slightly despite lower revenue. Management cited higher operating costs supporting more projects and recognition of deferred process-development costs.
- Research and development expense rose 59% for the quarter and 55% year to date, including increased AMR-001 trial and Treg program spending. SG&A declined year to date, but total operating expenses increased.
- Continuing-operations net loss worsened year to date. The much smaller consolidated net loss versus 2012 reflects substantial prior-year losses from discontinued China operations, rather than improved continuing-operations results.
- Cash from financing activities was $23.90 million for the first nine months, including proceeds from common-stock offerings, the Aspire equity line, and warrant and option exercises. Cash increased $3.21 million over that period.
Outlook, risks, and unusual items
- Management said it expected AMR-001 Phase 2 enrollment to finish in 2013, with an initial data readout six to eight months after the last patient infusion. As of November 6, 2013, 147 of 160 patients had been infused. The filing reports approximately $15.6 million incurred on the trial through September 30 and an estimated cost of up to $27 million over five years.
- PCT facility expansions in New Jersey and California were expected to be completed in the first quarter of 2014. Management also cited plans to expand manufacturing capacity and pursue international growth. These are expectations, not guarantees.
- On October 9, 2013, after quarter-end, the company completed an offering of 5.75 million shares, including the full over-allotment, at $7 per share, raising approximately $40.3 million gross before offering costs. This materially increased available liquidity after the balance-sheet date.
- Management warned that substantial additional capital may be needed for clinical development and business expansion, and that financing may not be available on acceptable terms. Equity financing may dilute shareholders; inability to raise capital could delay or curtail programs.
- PCT failed mortgage financial covenants at the December 2012 and June 2013 measurement dates and obtained lender waivers. One mortgage lender may call the loan at a 2017 reset date; the other loan is also subject to call provisions. Verify current covenant status and waiver terms.
- Other notable exposures include $7.55 million of acquisition-related contingent consideration, operating lease commitments of $2.71 million, and milestone, maintenance-fee, and royalty obligations under license arrangements. The filing says there were no material changes in previously disclosed legal proceedings or risk factors and no off-balance-sheet arrangements.
- The company reported effective disclosure controls at September 30, 2013. It also reported a transition to a new stock-plan financial reporting system effective July 1, 2013.
Most important facts for investors to verify
- Confirm the intended issuer and period: this filing is NeoStem’s 2013 Q3 report, despite the request metadata naming Lisata Therapeutics and 2012 Q3.
- Assess cash runway using the post-quarter offering proceeds against continuing operating cash use, trial costs, and planned facility expansion.
- Track completion of AMR-001 enrollment and the timing and results of the Phase 2 readout, as well as progress and funding needs for Treg and VSEL programs.
- Review PCT revenue mix, process-development contract completion timing, gross-margin trends, and whether increased clinical manufacturing activity converts to sustainable profitability.
- Check mortgage covenant compliance, waiver and call provisions, and potential dilution from outstanding equity-line capacity, options, warrants, and future financing.